The 2 most recently developed scores were designed to predict functional outcome after acute stroke, one in unselected acute ischemic stroke patients (Acute Stroke Registry and Analysis of Lausanne [ASTRAL]), 10 and the other in acute stroke patients treated with intravenous tPA (DRAGON includes dense middle cerebral artery sign, Background and Purpose-ASTRAL (Acute Stroke Registry and Analysis of Lausanne) and DRAGON (includes dense middle cerebral artery sign, prestroke modified Rankin Scale score, age, glucose, onset to treatment, National Institutes of Health Stroke Scale score) are 2 recently developed scores for predicting functional outcome after acute stroke in unselected acute ischemic stroke patients and in patients treated with intravenous thrombolysis, respectively. We aimed to perform external validation of these scores to assess their predictive performance in the large multicentre Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register. Methods-We calculated the ASTRAL and DRAGON scores in 36 131 and 33 716 patients, respectively, registered in Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register between 2003 and 2013. The proportion of patients with 3-month modified Rankin Scale scores of 3 to 6 was observed for each score point and compared with the predicted proportion according to the risk scores. Calibration was assessed using calibration plots, and predictive performance was assessed using area under the curve of the receiver operating characteristic. Multivariate logistic regression coefficients for the variables in the 2 scores were compared with the original derivation cohorts. 
F or many years, intravenous thrombolysis with tissue-type plasminogen activator (tPA) has been the only approved pharmacological treatment in the acute setting of ischemic stroke, associated with an improvement in functional outcome after stroke. 1, 2 Recently, several randomized studies have shown the benefits of endovascular thrombectomy as an additional/alternative treatment option. [3] [4] [5] Early identification of patients unlikely to benefit from timely delivery of intravenous tPA is important to transfer them directly to comprehensive stroke centers offering endovascular treatment. Several attempts have been made to create prognostication scores for patients with acute ischemic stroke, aiming to facilitate treatment decisions and communicate prognostic expectations to patients and families. [6] [7] [8] [9] [10] [11] [12] [13] [14] Stroke June 2016
prestroke modified Rankin Scale [mRS] score, age, glucose, onset to treatment, National Institutes of Health Stroke Scale [NIHSS] score). 6 ASTRAL was developed in a single-center stroke cohort, using multivariate logistic regression analysis. It consists of 6 readily available clinical parameters, not requiring acute imaging information: age at stroke onset (1 point per 5 years), baseline NIHSS score (1 point per NIHSS point), time from symptom onset to admission >3 hours (2 points), any stroke-related visual field defect (2 points), acute blood glucose >7.3 or <3.7 mmol/L (1 point), and decreased level of consciousness based on item 1a on the NIHSS (3 points). The ASTRAL score has previously been validated in 2 separate cohorts 15, 16 ; however, to our knowledge, there has not yet been a validation specifically in a thrombolyzed patient population. Validation in an intravenous tPA cohort is important as it may expand the role of the ASTRAL score for triage and treatment decisions in the acute setting. The DRAGON score was developed in a single-center cohort of acute ischemic stroke patients treated with intravenous tPA, using multivariate logistic regression analysis. It consists of 7 parameters, two of which require an admission head computed tomographic scan. The score ranges from 0 to 10, and the included parameters are hyperdense cerebral artery sign (1 point) and early infarct signs (1 point) on baseline computed tomographic, prestroke mRS score of >1 (1 point), age (<65 years=0 point, 65-79 years = 1 point, and ≥80 years = 2 points), acute blood glucose >8 mmol/L (1 point), time from symptom onset to treatment >90 minutes (1 point) and NIHSS score (0-4=0 point, 5-9=1 point, 10-15=2 points, and >15=3 points). The DRAGON score has previously been validated in 3 separate studies. [17] [18] [19] In this study, we aimed to validate these 2 risk scores in a global stroke thrombolysis database, the Safe Implementation of Thrombolysis in Stroke (SITS)-International Stroke Thrombolysis Register (ISTR). All parameters used in the ASTRAL and DRAGON scores are available in the SITS-ISTR. External validation of the 2 scores has to date shown promising results, and their validation in our large material should further encourage or discourage their use in candidates for intravenous thrombolysis treatment.
Methods

Study Population and Procedures
All patients registered in the SITS-ISTR between December 2002 and March 2013 were considered in the present study. All centers registering patients in SITS are required to accept the rules of participating in SITS-ISTR: consecutive registration of all patients with stroke symptoms receiving alteplase, irrespective of whether treatment was on-or off-label. Apart from treatment with alteplase, no inclusion or exclusion criteria were used. From the entire cohort data on 3-month mRS were available in 77.5% of cases. The SITS-ISTR is a multinational, prospective, observational monitoring register documenting data for centers using intravenous tPA in acute ischemic stroke. The aims of the register, collection of data, and structure of the database were described previously. 20 Baseline and demographic characteristics, stroke severity per the NIHSS, risk factors, time logistics, medication history, imaging data, and 3-month outcome data were registered. All patients performed a computed tomographic and magnetic resonance scan on admission. Assessments of imaging data and neurological status were undertaken according to clinical routine at participating centers.
Outcomes
Functional dependency at 3 months measured by mRS scores of 3 to 6 was the main outcome studied in the original ASTRAL cohort, and functional independency at 3 months measured by mRS score of 0 to 2 was the main outcome studied in the original DRAGON cohort.
Statistical Analysis
Descriptive analyses for baseline, demographic, and imaging data were performed, comparing the SITS-ISTR cohort with the ASTRAL and DRAGON cohorts, respectively ( Table 1 ). The analysis was performed after applying the inclusion/exclusion criteria used by each respective prognostic score in the original cohorts, and only patients with complete data for each respective score model were included in the analysis. The SITS-ISTR contains a proportion of the patients whose data were originally used in the DRAGON derivation cohort. All overlapping patients (n=1417) were excluded from the analysis. Proportions were calculated for categorical variables, dividing the number of events with the total number excluding missing/unknown cases. Median and mean values were calculated for numeric and ordinal variables. Median values were calculated for comparisons with DRAGON data where median values were originally presented, whereas mean values were calculated for comparisons with ASTRAL data where mean values were originally presented. For comparing proportions between scores, we used the χ 2 test. Differences between median data were not calculated as we did not have access to the original patient data from the DRAGON cohort. Student t tests were used for assessing differences between means.
Sensitivity, specificity, and predictive values for chosen point sum categories of the ASTRAL and DRAGON scores were calculated (Tables 2 and 3 , respectively). The area under the curve (AUC) of the receiver operating characteristic was calculated to assess the overall predictive and discriminative performance of the 2 scores. Calibration was assessed by plotting the observed probability of functional dependency in the SITS-ISTR cohort against the predicted probability based on the original scores (Figures 1  and 2 ). Curves depicting the predicted probability were calculated using the supplied multivariate logistic regression coefficients from the original studies. In addition, we fitted a second logistic regression model that allowed for the lower asymptote to be >0 and the upper asymptote to be <1. This second model permitted visual and quantitative assessment of the departure of the proportions observed in SITS from those predicted by the original scoring points, estimated by the vertical distance between the predicted and the actual outcome lines. These analyses were done for the ASTRAL score model and repeated for the DRAGON score model. A numeric comparison is reported in Tables I and II in the onlineonly Data Supplement.
Results
Between 2003 and 2013, a total of 36 131 intravenous tPAtreated patients with complete data for the ASTRAL score and 33 716 intravenous tPA-treated patients with complete data for the DRAGON score were registered in the SITS-ISTR. Table 1 shows our baseline data compared with the ASTRAL and DRAGON derivation cohorts. Only patients with complete data for the respective score, with complete outcome data, and fulfilling the original inclusion criteria for the respective score cohort are included. Where possible, comparisons between the SITS-ISTR and the 2 score cohorts were performed.
ASTRAL
As shown in Table 1 , mean age in the SITS cohort was close to 68 years, proportion of female patients 42.4% and acute glucose 7.1 mmol/L, when compared with the mean age of 68 years, 42.8% women and glucose 7.1 mmol/L reported from the ASTRAL cohort. 10 The proportion of patients with functionally independent outcome (mRS, 0-2) was 57.4% in the SITS-cohort and 66% in the ASTRAL cohort. Mean stroke severity as measured by NIHSS in the SITS-ISTR cohort was 12 compared with 9 in the ASTRAL cohort.
The onset-to-arrival time on average was lower in the SITS-ISTR cohort than in the ASTRAL cohort (82.2 versus 395.8 minutes).
The AUC-receiver operating characteristic value for functionally dependant outcome (mRS, 3-6) of the ASTRAL Table 2 shows the sensitivity, specificity, and positive likelihood ratio for different cutoff values of the ASTRAL score for functional dependency, comparing the SITS cohort with the original ASTRAL cohort. Increasing likelihood ratio for functional dependency is seen with increasing score cutoff. Figure 1 displays a calibration plot, comparing the predicted proportion of functionally dependant patients per ASTRAL score point based on the original ASTRAL cohort with the true proportions observed in the SITS cohort. Over the entire range of score points, the largest discrepancy between the observed and the predicted proportion of functional dependency was acceptable at 11%, ie, the maximum vertical distance between the predicted outcome line and the actual outcome line. With scores >46 points, larger discrepancies were seen; however, the number of patients at these high levels was low. ASTRAL underestimated the proportion of functional dependency in scores <40, and overestimated the proportion of functional dependency in scores >40. Table I in the online-only Data Supplement shows the regression coefficients for all parameters included in the ASTRAL cohort, for comparisons of the magnitude of the coefficients derived from the SITS-ISTR cohort compared with the original ASTRAL design cohort. All ASTRAL parameters except visual field defect were significantly associated with the outcome.
DRAGON
As shown in Table 1 , the median age in the SITS-ISTR population was 70, the proportion of women was 42.8%, and median baseline blood glucose was 6.5 mmol/L, compared with 69 years, 44.7% women, and 6.6 mmol/L glucose in the DRAGON derivation cohort. 6 Median NIHSS in the SITS cohort was 12 compared with 9 in the DRAGON cohort. The proportion of patients with a dense vessel sign on first noncontrast computed tomographic scan was only marginally different between the 2 groups (19.9% in the SITS cohort versus 17.7% in the DRAGON cohort), whereas proportions of early infarct signs differed more significantly (16.5% in the SITS cohort versus 30.6% in the DRAGON cohort). Although statistically significantly different, the proportions of patients with functionally independent outcome (mRS, 0-2) were comparable (56.2% versus 60.5%). The AUC-receiver operating characteristic value for functionally dependant outcome (mRS, 3-6) of the DRAGON score on the SITS-ISTR cohort was 0.77 (95% confidence interval, 0.769-0.779). Figure 2 displays a calibration plot, comparing the predicted proportion of functionally dependant patients per DRAGON score point based on the original DRAGON cohort with the true proportions observed in the SITS cohort. The DRAGON score generally overestimated the proportion of functional dependency, and the largest discrepancy between observed and predicted proportion of functionally dependent outcome was close to 17%, ie, the maximum vertical distance between the predicted outcome line and the actual outcome line. Table 3 shows the sensitivity, specificity, and positive likelihood ratio for different cutoff values of the DRAGON score for functional independency (mRS, 0-2) as it was done in original DRAGON score, comparing the SITS cohort with the original DRAGON cohort. Decreasing positive likelihood ratio for functional independency is seen with increasing score cutoff. Table II 
Discussion
In this to date largest validation attempt of ASTRAL and DRAGON, the 2 most recent outcome prediction scores in acute stroke showed promising performance with some limitations. To our knowledge, the current study is the first validation attempt of the ASTRAL score specifically in a thrombolyzed cohort. The DRAGON score has undergone external validation with promising results, [17] [18] [19] and our study confirms previous findings.
Both scores showed an acceptable or fair discriminative performance separating functional independency (mRS, 0-2) from functional dependency (mRS, 3-6), with AUC-receiver operating characteristic values of 0.79 (ASTRAL) and 0.77 (DRAGON), respectively. There are some differences between the SITS-ISTR and the ASTRAL and DRAGON derivation cohorts, as shown in Table 1 . The main differences between the SITS-ISTR and ASTRAL cohorts were higher mean baseline stroke severity (NIHSS, 12 versus 9) and a lower proportion of functional independence at 3 months in SITS, the latter likely explained by the higher stroke severity. The main difference between the SITS and the DRAGON cohorts was higher median baseline stroke severity, lower proportion of early infarct signs, and higher onset to treatment time in the SITS material. Despite these differences, calibration for the ASTRAL and DRAGON scores was acceptable in the SITS-ISTR cohort (Figures 1 and 2) . The largest discrepancy between predicted and actual outcome, comparing SITS-ISTR with ASTRAL and DRAGON and estimated from Figures 1 and 2 , amounted to 11% and 17%, respectively (larger discrepancies for ASTRAL at scores >46, but patient data here were limited). Although 11% and 17% may appear substantial, these are the maximum discrepancies observed, and the overall visual and numeric trend and concurrence between the predicted and the actual outcomes in the calibration plots are promising.
As shown in Tables 2 and 3 , both scores have positive likelihood ratios for functional outcome showing similar trends with increasing scores, as seen in the original cohorts. Although the exact magnitudes of the likelihood ratios were not identical, the DRAGON showed similar values, indicating the predictive value of the score. The likelihood ratios for the ASTRAL showed larger differences in absolute magnitude. However, these differences, especially at the highest score levels, need to be interpreted with caution. Patient numbers with such high scores were limited, which is apparent from visual assessment of the calibration plots, with wide confidence intervals at higher scores. The trend is however similar as in the original cohort, supporting the predictive value of the score.
Tables I and II in the online-only Data Supplement compare the magnitude of the regression coefficients for the ASTRAL and DRAGON derivation cohorts when compared with the coefficients obtained in the SITS-ISTR data. All parameters of the ASTRAL score apart from visual field defects were significantly associated with functionally dependent outcome in our material, with the level of consciousness and onset-to-admission time showing the largest discrepancy between our data and the original ASTRAL cohort. The reason for these discrepancies could be because of the fact that the SITS database is a thrombolysis register, whereas the ASTRAL data contained an unselected ischemic stroke cohort, including patients presenting late to stroke services, and who might not have been considered for acute treatment. A low level of consciousness can be associated with severe stroke, and NIHSS scores >25 remain a contraindication for intravenous tPA treatmentalbeit with questionable biological basis, as recently shown by our group. 21 This contraindication is likely causing a difference in the composition of the SITS and ASTRAL cohorts on this parameter. Overall, however, the mean NIHSS of the ASTRAL cohort was lower than the SITS cohort (9 versus 12, respectively), presumably because of the higher inclusion of patients with mild strokes, this probably being the main explanation for the higher proportion of favorable outcome in the ASTRAL cohort when compared with the SITS cohort (66% versus 57.4%). The difference in treatments between the 2 cohorts could probably also account for the difference in onset-to-admission time regression coefficients between the 2 cohorts, as thrombolyzed patients would be expected to arrive 
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June 2016 much earlier than the unselected cohort. For the DRAGON score, all included parameters were associated with functional outcome in the SITS-ISTR. The regression coefficients were relatively similar, the largest discrepancies between the SITS-ISTR and DRAGON cohorts seen in age ≥80 years and onset to treatment >90 minutes. These findings suggest a better prognostic value of the DRAGON score compared with the ASTRAL score, considering the included parameters better fit to the broad SITS-ISTR cohort. However, all-in-all, both the ASTRAL and the DRAGON, carry an acceptable prognostic value, considering both the calculated AUCs and the calibration plots. It is interesting that the discriminative performance of the ASTRAL, developed in an unselected ischemic stroke cohort, differed so little from the DRAGON score, which was developed using a thrombolysis cohort. We would have expected ASTRAL to underestimate good outcome and have a weaker performance in our thrombolysis cohort, but both showed a similar discriminative performance. The ASTRAL score has 1 potential advantage over the DRAGON: it requires no radiological imaging data to be calculated. This has implications for its use, as it may have a role in prehospital triage of acute stroke patients in conjunction with a prehospital scale for prediction of the presence of large artery occlusion, [22] [23] [24] guiding those with poor prognosticated outcome despite timely intravenous tPA treatment to centers performing endovascular thrombectomy for evaluation. This statement is based on our hypothesis that patients with higher scores, owing to the large impact of stroke severity on scoring, have a larger risk of harboring a proximal vessel occlusion amenable to endovascular intervention. The association between higher baseline NIHSS and the presence of vessel occlusion was recently shown in another publication from our group. 25 The importance of future studies separately investigating the association between score prediction and outcome after endovascular thrombectomy is evident.
Implementation of prehospital triage would demand an expansion of the inpatient capacity at receiving comprehensive centers because of a higher net inflow of patients. One important caveat that needs to be considered is the ≈15% to 20% proportion of intracranial hemorrhage in acute stroke. In this study, the ASTRAL score was validated on an ischemic stroke cohort, but if the ASTRAL score is used in a prehospital setting, the preimaging inclusion of intracranial hemorrhage patients might negatively affect its performance.
This study has certain limitations. It is based on a retrospective analysis of an ongoing database, bearing the limitations of such study design. The amount of missing data for 3-month follow-up of the mRS (22.5%) may have influenced the results. In the DRAGON study, patients with basilar artery occlusion were excluded from the analysis. Because of lacking data on the site of vessel occlusion in the SITS-ISTR, we were unable to identify and exclude these patients, possibly affecting the predictive capability of the DRAGON score in our patient cohort.
In conclusion, our study has validated the 2 most recently published stroke outcome prognostication tools and confirms their acceptable predictive value. The ASTRAL score does not require imaging data and therefore may have an advantage over the DRAGON for the use in prehospital patient assessment. Prospective studies of both scores evaluating the impact of their use on patient outcomes after intravenous thrombolysis and endovascular therapy are needed.
Sources of Funding
This study is a part of the project The coefficients reported in the middle columns of Supplemental Tables I and II were obtained by fitting logistic regression models with the predictors of the ASTRAL and DRAGON scores respectively with the SITS-ISTR data. For ease of comparison, the leftmost columns in Supplemental Tables I and II contain the corresponding coefficients published in the original ASTRAL and DRAGON articles.
SUPPLEMENTAL MATERIAL
